Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic ...
Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...
Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...
Moderna's Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results